Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCC

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses what therapy to give patients with renal cell carcinoma (RCC) after they have received a PD-1/PD-L1 blockade.

Choueiri is not aware of any studies that look into subsequent therapies after a PD-1/PD-L1 blockade, but he wonders if patients should continue to receive the PD-1/PD-L1 inhibitors since the checkpoint inhibitors are very similar with one another.

With the JAVELIN Renal 101 study of avelumab (Bavencio) plus axitinib (Inlyta), Choueiri suggests examining the combination versus axitinib alone versus avelumab alone versus sunitinib (sutent). Choueiri hopes such a clinical trial is created soon to decipher the contributions of each agent in untreated patients with RCC.